Kuvatris Therapeutics, Inc.
PXMDDelisted Aug 8, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001811623
Kuvatris Therapeutics, Inc. was delisted on Aug 8, 2025; its insiders filed their last Form 4 on Mar 14, 2024; no institution reported holding it in 13F filings for Q2 2025; no superinvestor held it.
13F holders, Q4 2023
Institutional positions in Kuvatris Therapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 9
- −4 vs. Q3 2023
- Shares held
- 110.8K
- −185.4K (−62.6%) vs. Q3 2023
- Total value
- $84.2K
- −$1.65K (−1.9%) vs. Q3 2023
- New holders
- 3
- 1 more added
- Sold out
- 7
- 5 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PXMD on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 1 | $12 |
| Q1 2024 | 8 | $64.7K |
| Q4 2023 | 9 | $84.2K |
| Q3 2023 | 13 | $85.8K |
| Q2 2023 | 8 | $165.3K |
| Q1 2023 | 10 | $307.6K |
| Q4 2022 | 8 | $176.0K |
| Q3 2022 | 6 | $155.0K |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Kuvatris Therapeutics, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Virtu Financial LLC | 56,441 | $43.0K | 0.00% | +56,441 | New |
| Citadel Advisors LLC | 27,973 | $21.2K | 0.00% | +27,973 | New |
| Two Sigma Securities, LLC | 11,148 | $8.44K | 0.00% | +11,148 | New |
| Tower Research Capital LLC (TRC) | 6,747 | $5.11K | 0.00% | −1,138−14.4% | Reduced |
| JPMorgan Chase & Co | 5,699 | $4.31K | 0.00% | +5,695+142,375.0% | Added |
| Clearstead Advisors, LLC | 2,244 | $1.70K | 0.00% | −35,912−94.1% | Reduced |
| UBS Group AG | 491 | $372 | 0.00% | −607−55.3% | Reduced |
| Advisor Group Holdings, Inc. | 58 | $43 | 0.00% | −1,942−97.1% | Reduced |
| Wells Fargo & Company | 2 | $2 | 0.00% | −33−94.3% | Reduced |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −97,100−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −54,959−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −31,034−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −30,781−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −21,900−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −10,773−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −500−100.0% | Sold out |